EUROASPIRE V/ASPIRE-3-PREVENT

  • Research type

    Research Study

  • Full title

    EUROASPIRE V/ ASPIRE-3-PREVENT survey on Cardiovascular Disease Prevention and Diabetes

  • IRAS ID

    198231

  • Contact name

    Kornelia Kotseva

  • Contact email

    k.kotseva@imperial.ac.uk

  • Sponsor organisation

    Imperial College London and Imperial College Healthcare NHS Trust

  • Duration of Study in the UK

    2 years, 11 months, 31 days

  • Research summary

    EUROASPIRE is a multicentre European study in coronary patients and individuals at high risk of developing cardiovascular disease (CVD), describing their management through lifestyle and use of drug therapies and providing an objective assessment of clinical implementation of current scientific knowledge. Four EUROASPIRE surveys have been carried out by the European Society of Cardiology so far: EUROASPIRE I in 1995-1997 in nine countries, EUROASPIRE II in 1999- 2000 in 15 countries, EUROASPIRE III in 2006-2009 in 22 countries and EUROASPIRE IV in 2012-2015 in 26 countries. The results showed a wide gap between the recommendations and clinical practice with many patients not achieving the lifestyle and medical risk factors goals for CVD prevention. The fifth EUROASPIRE survey is planned for 2016-2018 to determine in hospital coronary patients and apparently healthy individuals in primary care at high risk of developing cardiovascular disease whether the European and national guidelines on cardiovascular disease prevention have been followed and if the practice of preventive
    cardiology in EUROASPIRE IV has improved by comparison with those centres which took part in EUROASPIRE I, II, III and IV. This survey will also incorporate an assessment of dysglycaemia and kidney function in all patients. The main outcome measures will be the proportions of coronary and high cardiovascular risk patients achieving the lifestyle, risk factor and therapeutic targets for cardiovascular disease prevention. The data collection will be based on a review of patient medical records and a patient interview and examination at least 6 months and at most 3 years after recruiting event. All countries which participated in the first three surveys will be invited to take part in EUROASPIRE V. This fifth survey
    will give a unique picture of preventive action by cardiologists and primary care physicians looking
    after patients with coronary disease and individuals at high CVD risk.

  • REC name

    London - Central Research Ethics Committee

  • REC reference

    16/LO/0432

  • Date of REC Opinion

    1 Apr 2016

  • REC opinion

    Favourable Opinion